← Back to Search

Device

Smart Cuff Group for High Blood Pressure

N/A

Recruiting

Led By David Shalowitz

Research Sponsored by West Michigan Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 18 months

Awards & highlights

Study Summary

This trial is testing whether using remote blood pressure monitoring is better than regular care for patients taking bevacizumab. They want to see if remote monitoring helps to collect blood pressure data, identify and

Who is the study for?

This trial is for cancer patients with high blood pressure who are being treated with bevacizumab. It's designed to see if monitoring blood pressure remotely can help manage hypertension better and improve patient satisfaction.Check my eligibility

What is being tested?

The study compares two groups: one uses a cellular-enabled blood pressure cuff for remote monitoring, while the other group follows usual care practices without remote technology.See study design

What are the potential side effects?

Potential side effects may relate more to the treatment with bevacizumab, which can include high blood pressure, bleeding, poor wound healing, and in some cases, kidney problems.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 18 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 18 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

To determine whether remote blood pressure monitoring improves adherence to recommendations for daily systolic and diastolic blood pressure monitoring compared to usual care

Secondary outcome measures

Improvement of early identification of bevacizumab-induced hypertension with remote blood pressure monitoring

Improvement of early identification of bevacizumab-induced hypertension with usual care blood pressure monitoring

Patient satisfaction with remote blood pressure monitoring

+1 more

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: Smart Cuff GroupActive Control1 Intervention

Smart blood pressure cuff

Group II: Control GroupPlacebo Group1 Intervention

Standard of care

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

West Michigan Cancer CenterLead Sponsor

1 Previous Clinical Trials

100 Total Patients Enrolled

Veta HealthUNKNOWN

David ShalowitzPrincipal InvestigatorWest Michigan Cancer Center

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current number of individuals being enrolled in this research investigation?

"Indeed, information from clinicaltrials.gov highlights that this research study is actively seeking eligible individuals. This trial was first listed on March 11, 2024 and last modified on April 9, 2024. Enrollment aims to recruit a total of 72 participants at a single designated site."

Answered by AI

Are there any available vacancies for patient participation in this clinical trial?

"Based on information from clinicaltrials.gov, this research project is actively pursuing participants. The trial was initially shared on March 11th, 2024, and most recently revised on April 9th of the same year."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Expanding Access to Care Through Telemedical Support for Vital Sign Monitoring in High-risk Patients With Cancer

David Shalowitz 2024. "Expanding Access to Care Through Telemedical Support for Vital Sign Monitoring in High-risk Patients With Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06364748.